Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients

Company Unveils Phase II/III Relatlimab Combo Data At ASCO

Executive Summary

Data show better safety than Opdivo/Yervoy, though what appears to be slightly lower efficacy, in first-line metastatic or unresectable melanoma.

You may also be interested in...



Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises

Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.

ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations

Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.

BMS Jumps Ahead With LAG-3 Melanoma Data

LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel